Particle Therapy Market

Particle Therapy Market by Type (Proton Therapy, Heavy Ion), Products (Cyclotron, Synchrotron, Synchrocyclotron), Services, System (Single-room, Multi-room), Cancer Type (Pediatric, Prostate), Application (Treatment, Research) - Global Forecast to 2028

Report Code: MD 6747 Nov, 2023, by marketsandmarkets.com

The global particle therapy market in terms of revenue was estimated to be worth $0.7 billion in 2023 and is poised to reach $1.1 billion by 2028, growing at a CAGR of 8.2% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The rise of particle therapy can be seen due to the following drivers -particle therapy can reduce the risk of long-term side effects. The ability to spare healthy tissues from unnecessary radiation exposure is especially important for improving the quality of life for cancer survivors; Technological advancements have made particle therapy more accessible and cost-effective. The development of compact and less expensive proton therapy systems has contributed to the expansion of particle therapy facilities, and increased availability of treatment centers among others.

Attractive Opportunities in the Particle Therapy Market

Particle  Therapy Market

To know about the assumptions considered for the study, Request for Free Sample Report

Particle  Therapy Market

Particle therapy market: Market Dynamics

Driver: Growing global prevalence of cancer

Global demand for particle therapy (heavy-ion and proton therapy) is being driven largely by the rising incidence of cancer. The American Cancer Society estimates that there will be about 1.9 million new cancer cases diagnosed in the United States in 2021. According to estimates from the World Cancer Research Fund, there will be 19.3 million new cases of cancer worldwide in 2021; by 2035, this number is predicted to rise by 24 million. Consequently, the market for particle therapy will expand in tandem with the rising incidence of pediatric cancer.

Increasing number of particle therapy centers worldwide

The number of particle therapy centers is increasing globally. At the beginning of 2020, there were 37 proton therapy centers in the US alone and a total of 89 worldwide (Source: HealthPACT). From 2010 to 2016, 16 of a total of 23 proton treatment centers (70%) in the US began operations, showing an increase in the number of proton centers in the country.

Growing government initiatives toward establishing particle therapy centers across regions are also driving the adoption of particle therapy as an alternative to traditional radiation therapy for cancer. The second NHS center is currently being built at University College London Hospitals (UCLH), which will gradually ramp up proton beam therapy activity during 2021. When complete, the two centers will each treat up to 750 patients every year.

Restraint: Affordability and accessibility of treatments

Particle therapy demands sophisticated machinery in addition to additional services like dose management software, customized treatment planning, and patient positioning. The involvement of numerous healthcare professionals throughout the entire treatment cycle raises the procedure's overall cost. In addition to having extremely sophisticated features and functionalities for treating various cancers, particle systems are also highly expensive. It becomes challenging for small hospitals and institutions to make such a large capital investment in a particle therapy center, particularly in low- and middle-income nations. Consequently, despite the rising incidence of cancer, the adoption rate of these devices is low.

Unfavorable reimbursement policies and limited insurance coverage for particle therapy

Proton beam therapy and heavy-ion therapy are both increasingly gaining acceptance as either the first modes of treatment or combination therapies with other methods of cancer treatment, including chemotherapy, proton therapy, and surgery. However, particle therapy treatments lack proper reimbursements in developed and developing countries, which is a major factor restraining the growth of this market.

Opportunity: Rising healthcare expenditure across developing countries

In several developing nations, including China, India, Brazil, and Mexico, there is a likelihood that access to high-quality healthcare will increase due to their swift economic growth and rising healthcare spending. This is regarded as a sign of strength for the particle therapy industry. The need for different particle therapy tools and methods is increasing as a result of the increased cancer incidence in these nations. Furthermore, the governments of these nations are concentrated on expanding access to modern and cutting-edge healthcare services for greater segments of their populations and enhancing reimbursement coverage. The expansion of healthcare products (including oncology devices) across these nations is being driven by the quick increase in per-capita healthcare spending as well as the growing public demand for affordable healthcare services. The overall rise in healthcare spending serves as evidence of this. For instance, between 2019 and 2020, India's healthcare spending rose from 1.2% to 2.5% of GDP. Due to government spending increases in the healthcare sector during the COVID-19 pandemic, healthcare spending in China has increased by 12.6% to approximately USD 930 billion. [Source: Asia's Healthcare]

Challenge: Increasing risk of radiation exposure

The elevated risk of radiation exposure is one of the main obstacles to using particle therapy to treat cancer. The high radiation doses associated with therapeutic exposures carry the risk of harming not only the patients choosing the course of treatment, but also the medical staff and those in the immediate vicinity in the event of an unintentional radiation exposure. Nausea, vomiting, and diarrhea are just a few of the negative effects that could arise from this. Comparably, a high dose of radiation received all at once can result in radiation sickness and even death.

Particle Therapy
Market Ecosystem

Major companies in this market include well-established and financially stable suppliers of particle therapy market. Prominent companies in this market include Varian Medical Systems, Inc.(US) IBA Worldwide(EU) and Hitachi (Japan), among several others.

Particle  Therapy Market Ecosystem

The Products segment of the particle therapy industry is witnessed to grow at the highest CAGR during the forecast periods 2022-2028.

By Product& Services, the Product segment accounted for the largest share of the particle therapy market in 2022. Particle therapy is one of the most popular alternative treatment procedures for radiation therapy. With particle therapy systems, the precise delivery of the radiation dose to the required tumor site is achieved. Particle therapy products include particle accelerators that are used to deliver proton therapy or heavy-ion therapy.

The Pediatric cancer-type segment accounted for the highest CAGR of the particle therapy industry in 2022-2028

Based on the cancer type, the particle therapy market is segmented into pediatric cancers, prostate, cancer, lung cancer, head and neck cancer, and other cancers. Pediatric cancer accounted for the largest share in 2022 due to reasons like genetic predisposition, and immature immune system. In children, normal healthy cells are more vulnerable to ionized particles owing to the high rate of mitosis. It is, therefore, crucial to aim radiation beams only at the tumor to lower the risk of side effects, such as cognitive impairments, radiation-induced tumors, cardiac damage, and other complications later in the lifetime. As protons can be controlled precisely, proton therapy is ideal for pediatric tumors located near growing tissues in the spinal cord, brain, eyes, ears, or mouth.

Treatment application for the highest growth rate of the particle therapy industry in 2022-2028

The application segment of the particle therapy market is divided into treatment application and research application. Treatment applications accounts for the largest share in the particle therapy market in 2022. The growing number of cancer patients, increasing government initiatives aimed at equipping or upgrading hospitals with newer and advanced radiotherapy systems, increasing availability of funding for the adoption of advanced cancer treatment technologies, and the rising adoption of particle therapy devices & procedures as a primary treatment option globally are factors driving the growth of this segment

North America is expected to be the largest market for the particle therapy industry during the forecast period.

In 2022, the US and Canada accounted for the majority of the particle therapy market in North America. North America offers the perfect environment for the adoption of cutting-edge treatment methodologies like particle therapy market due to its robust healthcare infrastructure and availability of cutting-edge medical technologies. In the healthcare industry, research and development are prioritized heavily in North America. Proton therapy is one of the many medical technologies being advanced by a plethora of research institutes, medical schools, and private businesses.Access to cutting-edge treatments is made easier in North America by the widespread availability of health insurance and coverage. For patients seeking proton therapy and other cutting-edge medical services, this lowers financial barriers.

Particle  Therapy Market by Region

To know about the assumptions considered for the study, download the pdf brochure

As of 2022, prominent players in the market are IBA Worldwide (EU), Varian Medical Systems (US), and Hitachi (Japan), among others.

Scope of the Particle Therapy Industry

Report Metric

Details

Market Revenue in 2023

$0.7 billion

Projected Revenue by 2028

$1.1 billion

Revenue Rate

Poised to Grow at a CAGR of 8.2%

Market Driver

Growing global prevalence of cancer

Market Opportunity

Rising healthcare expenditure across developing countries

This report has segmented the global particle therapy market to forecast revenue and analyze trends in each of the following submarkets:

By Type

  • Proton therapy
  • Heavy-Ion therapy

By Product & Services

  • Products
  • Services

By System

  • Multi-room systems
  • Single-room systems

By Application

  • Treatment application
  • Research application

By Cancer-type

  • Paediatric Cancer
  • Lung Cancer
  • Breast cancer
  • Head and
  • Other cancers

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
  • MEA

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 28)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
    1.3 INCLUSIONS & EXCLUSIONS 
    1.4 MARKET SCOPE 
           1.4.1 MARKETS COVERED
           1.4.2 REGIONS COVERED
           1.4.3 YEARS CONSIDERED
           1.4.4 CURRENCY CONSIDERED
                    TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
    1.5 STAKEHOLDERS 
    1.6 SUMMARY OF CHANGES 
           1.6.1 RECESSION IMPACT: PARTICLE THERAPY MARKET
 
2 RESEARCH METHODOLOGY (Page No. - 33)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    2.1.2.1 Key primary sources
                    2.1.2.2 Key data from primary sources
                    2.1.2.3 Breakdown of primaries
                                FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY END USER, DESIGNATION, AND REGION
                    2.1.2.4 Key industry insights
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2022
          FIGURE 5 SUPPLY-SIDE ANALYSIS
          FIGURE 6 TOP-DOWN APPROACH
          FIGURE 7 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
          FIGURE 8 CAGR PROJECTIONS
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 9 DATA TRIANGULATION METHODOLOGY
    2.4 RESEARCH LIMITATIONS 
           2.4.1 SCOPE-RELATED LIMITATIONS
           2.4.2 METHODOLOGY-RELATED LIMITATIONS
    2.5 RISK ASSESSMENT 
    2.6 STUDY ASSUMPTIONS 
           2.6.1 IMPACT OF RECESSION ON PARTICLE THERAPY MARKET
 
3 EXECUTIVE SUMMARY (Page No. - 46)
    FIGURE 10 PARTICLE THERAPY MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 11 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
    FIGURE 12 PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 PARTICLE THERAPY MARKET, BY SYSTEM, 2023 VS. 2028 (USD MILLION)
    FIGURE 14 PARTICLE THERAPY MARKET, BY CANCER TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 15 PARTICLE THERAPY MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    FIGURE 16 GEOGRAPHICAL SNAPSHOT OF PARTICLE THERAPY MARKET
 
4 PREMIUM INSIGHTS (Page No. - 51)
    4.1 PARTICLE THERAPY MARKET OVERVIEW 
          FIGURE 17 INCREASING PREVALENCE OF CANCER TO DRIVE MARKET
    4.2 REGIONAL MIX: PARTICLE THERAPY MARKET 
          FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD
    4.3 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY TYPE AND COUNTRY (2022) 
          FIGURE 19 PROTON THERAPY ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2022
    4.4 PARTICLE THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 20 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
    4.5 DEVELOPED VS. EMERGING ECONOMIES: PARTICLE THERAPY MARKET 
          FIGURE 21 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 55)
    5.1 INTRODUCTION 
          FIGURE 22 PARTICLE THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.1.1 DRIVERS
                    5.1.1.1 Advantages of particle therapy over photon therapy
                    5.1.1.2 Growing prevalence of cancer
                    5.1.1.3 Rising adoption of particle therapy in clinical trials
                    5.1.1.4 Increasing number of particle therapy centers worldwide
                    5.1.1.5 Technological advancements
           5.1.2 RESTRAINTS
                    5.1.2.1 Infrastructural challenges in healthcare facilities
                    5.1.2.2 Affordability and accessibility of treatments
                    5.1.2.3 Unfavorable reimbursement policies and limited insurance coverage for particle therapy
           5.1.3 OPPORTUNITIES
                    5.1.3.1 Growth potential of emerging economies
           5.1.4 CHALLENGES
                    5.1.4.1 Difficulties in visualizing tumors during particle therapy procedures
                    5.1.4.2 Potential for unwanted radiation exposure
    5.2 ECOSYSTEM/MARKET MAP 
          FIGURE 23 PARTICLE THERAPY MARKET: ECOSYSTEM ANALYSIS
    5.3 PRICING ANALYSIS 
    5.4 SUPPLY CHAIN ANALYSIS 
          FIGURE 24 SUPPLY CHAIN ANALYSIS: PARTICLE THERAPY MARKET
    5.5 PATENT ANALYSIS 
           5.5.1 PATENT PUBLICATION TRENDS FOR PARTICLE THERAPY MARKET
                    FIGURE 25 TOTAL PATENTS GRANTED FROM 2012–2022
                    FIGURE 26 TOP PATENT APPLICANTS IN PARTICLE THERAPY
                    FIGURE 27 TOP PATENT OWNERS IN PARTICLE THERAPY
    5.6 VALUE CHAIN ANALYSIS 
          FIGURE 28 PARTICLE THERAPY MARKET: VALUE CHAIN ANALYSIS
    5.7 TECHNOLOGY ANALYSIS 
    5.8 KEY CONFERENCES & EVENTS IN 2023–2024 
    5.9 REGULATORY LANDSCAPE 
          TABLE 2 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 3 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 4 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 5 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 6 REGULATORY STANDARDS/APPROVALS REQUIRED FOR PARTICLE THERAPY PRODUCTS BY COUNTRY/REGION
    5.10 REIMBURSEMENT ANALYSIS 
           TABLE 7 MEDICAL REIMBURSEMENT CODES FOR PARTICLE THERAPY PROCEDURES IN US, 2022
    5.11 TRADE ANALYSIS 
           TABLE 8 INSTALLED BASE OF RADIOTHERAPY DEVICES
    5.12 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 9 PARTICLE THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.12.1 THREAT OF NEW ENTRANTS
           5.12.2 THREAT OF SUBSTITUTES
           5.12.3 BARGAINING POWER OF SUPPLIERS
           5.12.4 BARGAINING POWER OF BUYERS
           5.12.5 DEGREE OF COMPETITION
    5.13 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE APPLICATIONS
                     TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE APPLICATIONS (%)
           5.13.2 BUYING CRITERIA
                     FIGURE 30 KEY BUYING CRITERIA FOR TOP THREE APPLICATIONS
                     TABLE 11 KEY BUYING CRITERIA FOR TOP THREE APPLICATIONS
    5.14 CASE STUDY ANALYSIS 
           TABLE 12 CASE STUDY: ENHANCING PATIENT SAFETY—RT’S ROLE IN MINIMIZING RADIATION RISK IN AN ELDERLY PATIENT (90-YEAR-OLD FEMALE WITH A MEDICALLY INOPERABLE EARLY-STAGE NSCLC)
    5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 
           FIGURE 31 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX
 
6 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE (Page No. - 75)
    6.1 INTRODUCTION 
          TABLE 13 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
    6.2 PRODUCTS 
          TABLE 14 PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 15 PARTICLE THERAPY PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION)
           6.2.1 CYCLOTRONS
                    6.2.1.1 Advantages offered by cyclotrons over other accelerators to drive market
                                TABLE 16 CYCLOTRONS MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 17 NORTH AMERICA: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 18 EUROPE: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 19 ASIA PACIFIC: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 20 LATIN AMERICA: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.2.2 SYNCHROTRONS
                    6.2.2.1 Increasing investments for development of synchrotron facilities to aid market growth
                                TABLE 21 SYNCHROTRONS MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 22 NORTH AMERICA: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 23 EUROPE: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 24 ASIA PACIFIC: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 25 LATIN AMERICA: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.2.3 SYNCHROCYCLOTRONS
                    6.2.3.1 High space requirements to limit adoption
                                TABLE 26 SYNCHROCYCLOTRONS MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 27 NORTH AMERICA: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 28 EUROPE: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 29 ASIA PACIFIC: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 30 LATIN AMERICA: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 SERVICES 
           6.3.1 AVAILABILITY OF WIDE RANGE OF SERVICES TO PROPEL MARKET
                    TABLE 31 PARTICLE THERAPY SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 32 NORTH AMERICA: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 33 EUROPE: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 34 ASIA PACIFIC: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 35 LATIN AMERICA: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
 
7 PARTICLE THERAPY MARKET, BY TYPE (Page No. - 87)
    7.1 INTRODUCTION 
          TABLE 36 PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
    7.2 PROTON THERAPY 
           7.2.1 GROWING ADOPTION AS PRIMARY TREATMENT FOR VARIOUS CANCER TYPES TO DRIVE MARKET
                    TABLE 37 PROTON THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION)
    7.3 HEAVY ION THERAPY 
           7.3.1 SLOWER GROWTH ATTRIBUTED TO EXPERIMENTAL PHASE ACROSS MANY REGIONS
                    TABLE 38 HEAVY ION THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION)
 
8 PARTICLE THERAPY MARKET, BY SYSTEM (Page No. - 91)
    8.1 INTRODUCTION 
          TABLE 39 PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION)
    8.2 MULTI-ROOM SYSTEMS 
           8.2.1 LOWER SHIELDING REQUIREMENTS AND FASTER BEAM-SWITCHING CAPABILITIES TO DRIVE INTEREST AMONG END USERS
                    TABLE 40 PARTICLE THERAPY MARKET FOR MULTI-ROOM SYSTEMS, BY REGION, 2021–2028 (USD MILLION)
    8.3 SINGLE-ROOM SYSTEMS 
           8.3.1 COMPACT STRUCTURE AND REDUCED CAPITAL COST TO PROPEL GROWTH
                    TABLE 41 PARTICLE THERAPY MARKET FOR SINGLE-ROOM SYSTEMS, BY REGION, 2021–2028 (USD MILLION)
 
9 PARTICLE THERAPY MARKET, BY APPLICATION (Page No. - 95)
    9.1 INTRODUCTION 
          TABLE 42 PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
    9.2 TREATMENT APPLICATIONS 
           9.2.1 INTRODUCTION OF SMALL FOOTPRINT SINGLE-ROOM PARTICLE THERAPY CENTERS TO SUPPORT MARKET GROWTH
                    TABLE 43 PARTICLE THERAPY MARKET FOR TREATMENT APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
    9.3 RESEARCH APPLICATIONS 
           9.3.1 INCREASING AVAILABILITY OF FUNDING FOR PARTICLE THERAPY-RELATED RESEARCH PROJECTS TO PROVIDE GROWTH OPPORTUNITIES
                    TABLE 44 PARTICLE THERAPY MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
 
10 PARTICLE THERAPY MARKET, BY CANCER TYPE (Page No. - 99)
     10.1 INTRODUCTION 
             TABLE 45 PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION)
     10.2 PEDIATRIC CANCER 
             10.2.1 INCREASING CASES OF PEDIATRIC CANCER TO PROPEL MARKET
                        TABLE 46 PARTICLE THERAPY MARKET FOR PEDIATRIC CANCER, BY REGION, 2021–2028 (USD MILLION)
     10.3 PROSTATE CANCER 
             10.3.1 ADVANTAGES OFFERED BY PARTICLE THERAPY FOR TREATMENT OF PROSTATE CANCER TO DRIVE MARKET
                        TABLE 47 PARTICLE THERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2021–2028 (USD MILLION)
     10.4 LUNG CANCER 
             10.4.1 GROWING CLINICAL TESTING OF PROTON THERAPY FOR LUNG CANCER TO DRIVE MARKET
                        TABLE 48 PARTICLE THERAPY MARKET FOR LUNG CANCER, BY REGION, 2021–2028 (USD MILLION)
     10.5 BREAST CANCER 
             10.5.1 LIMITED RADIATION EXPOSURE WITH REDUCED SIDE-EFFECTS TO INCREASE ADOPTION OF PARTICLE THERAPY
                        TABLE 49 PARTICLE THERAPY MARKET FOR BREAST CANCER, BY REGION, 2021–2028 (USD MILLION)
     10.6 HEAD & NECK CANCER 
             10.6.1 USE OF PENCIL-BEAM SCANNING FOR PROTON THERAPY TO SUPPORT MARKET GROWTH
                        TABLE 50 PARTICLE THERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 2021–2028 (USD MILLION)
     10.7 OTHER CANCERS 
             TABLE 51 PARTICLE THERAPY MARKET FOR OTHER CANCERS, BY REGION, 2021–2028 (USD MILLION)
 
11 PARTICLE THERAPY MARKET, BY REGION (Page No. - 105)
     11.1 INTRODUCTION 
             TABLE 52 PARTICLE THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION)
     11.2 NORTH AMERICA 
             11.2.1 NORTH AMERICA: RECESSION IMPACT
                        FIGURE 32 NORTH AMERICA: PARTICLE THERAPY MARKET SNAPSHOT
                        TABLE 53 NORTH AMERICA: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 54 NORTH AMERICA: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 55 NORTH AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 56 NORTH AMERICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 57 NORTH AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION)
                        TABLE 58 NORTH AMERICA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION)
                        TABLE 59 NORTH AMERICA: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             11.2.2 US
                        11.2.2.1 Growing number of particle therapy centers to drive market growth
                                      TABLE 60 US: MACROECONOMIC INDICATORS
                                      TABLE 61 US: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 62 US: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
             11.2.3 CANADA
                        11.2.3.1 Government initiative to include particle therapy as treatment method to boost market
                                      TABLE 63 CANADA: MACROECONOMIC INDICATORS
                                      TABLE 64 CANADA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 65 CANADA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
     11.3 EUROPE 
             11.3.1 EUROPE: RECESSION IMPACT
                        TABLE 66 EUROPE: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 67 EUROPE: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 68 EUROPE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 69 EUROPE: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 70 EUROPE: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION)
                        TABLE 71 EUROPE: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION)
                        TABLE 72 EUROPE: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             11.3.2 GERMANY
                        11.3.2.1 Increasing research on proton and heavy ion therapy to drive market growth
                                      TABLE 73 GERMANY: MACROECONOMIC INDICATORS
                                      TABLE 74 GERMANY: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 75 GERMANY: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
             11.3.3 FRANCE
                        11.3.3.1 Increasing healthcare expenditure to support particle therapy product adoption
                                      TABLE 76 FRANCE: MACROECONOMIC INDICATORS
                                      TABLE 77 FRANCE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 78 FRANCE: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
             11.3.4 UK
                        11.3.4.1 Increasing acceptance of particle therapy techniques in cancer treatment to support market growth
                                      TABLE 79 UK: MACROECONOMIC INDICATORS
                                      TABLE 80 UK: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 81 UK: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
             11.3.5 ITALY
                        11.3.5.1 Increasing awareness activities to support market growth
                                      TABLE 82 ITALY: MACROECONOMIC INDICATORS
                                      TABLE 83 ITALY: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 84 ITALY: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
             11.3.6 SPAIN
                        11.3.6.1 Increasing number of conferences and government funding for cancer research to drive market
                                      TABLE 85 SPAIN: MACROECONOMIC INDICATORS
                                      TABLE 86 SPAIN: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 87 SPAIN: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
             11.3.7 REST OF EUROPE
                        TABLE 88 REST OF EUROPE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 89 REST OF EUROPE: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
     11.4 ASIA PACIFIC 
             11.4.1 ASIA PACIFIC: RECESSION IMPACT
                        FIGURE 33 ASIA PACIFIC: PARTICLE THERAPY MARKET SNAPSHOT
                        TABLE 90 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 91 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 92 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 93 ASIA PACIFIC: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 94 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION)
                        TABLE 95 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION)
                        TABLE 96 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             11.4.2 JAPANa
                        11.4.2.1 Increasing use of heavy ion therapy for cancer treatment to propel market
                                      TABLE 97 JAPAN: MACROECONOMIC INDICATORS
                                      TABLE 98 JAPAN: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 99 JAPAN: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
             11.4.3 CHINA
                        11.4.3.1 High cancer burden to drive market
                                      TABLE 100 CHINA: MACROECONOMIC INDICATORS
                                      TABLE 101 CHINA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 102 CHINA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
             11.4.4 INDIA
                        11.4.4.1 Improving research capabilities to support market growth
                                      TABLE 103 INDIA: MACROECONOMIC INDICATORS
                                      TABLE 104 INDIA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 105 INDIA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
             11.4.5 AUSTRALIA
                        11.4.5.1 Healthcare funding availability to boost market growth
                                      TABLE 106 AUSTRALIA: MACROECONOMIC INDICATORS
                                      TABLE 107 AUSTRALIA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 108 AUSTRALIA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
             11.4.6 SOUTH KOREA
                        11.4.6.1 Rising prevalence of cancer to drive market
                                      TABLE 109 SOUTH KOREA: MACROECONOMIC INDICATORS
                                      TABLE 110 SOUTH KOREA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 111 SOUTH KOREA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
             11.4.7 REST OF ASIA PACIFIC
                        TABLE 112 REST OF ASIA PACIFIC: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 113 REST OF ASIA PACIFIC: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
     11.5 LATIN AMERICA 
             11.5.1 LATIN AMERICA: RECESSION IMPACT
                        TABLE 114 LATIN AMERICA: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 115 LATIN AMERICA: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 116 LATIN AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 117 LATIN AMERICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 118 LATIN AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION)
                        TABLE 119 LATIN AMERICA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION)
                        TABLE 120 LATIN AMERICA: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             11.5.2 BRAZIL
                        11.5.2.1 Government initiates to propel market growth
                                      TABLE 121 BRAZIL: MACROECONOMIC INDICATORS
                                      TABLE 122 BRAZIL: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 123 BRAZIL: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
             11.5.3 MEXICO
                        11.5.3.1 Growing adoption of advanced medical technologies to drive market
                                      TABLE 124 MEXICO: MACROECONOMIC INDICATORS
                                      TABLE 125 MEXICO: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 126 MEXICO: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
             11.5.4 REST OF LATIN AMERICA
                        TABLE 127 REST OF LATIN AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 128 REST OF LATIN AMERICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
     11.6 MIDDLE EAST & AFRICA 
             11.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET
             11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
                        TABLE 129 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 130 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 131 MIDDLE EAST & AFRICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 132 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION)
                        TABLE 133 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION)
                        TABLE 134 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
 
12 COMPETITIVE LANDSCAPE (Page No. - 149)
     12.1 OVERVIEW 
     12.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             FIGURE 34 KEY DEVELOPMENTS IN PARTICLE THERAPY MARKET
     12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 
             FIGURE 35 REVENUE ANALYSIS OF TOP PLAYERS IN PARTICLE THERAPY MARKET
     12.4 MARKET SHARE ANALYSIS 
             FIGURE 36 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022
     12.5 COMPANY EVALUATION MATRIX 
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                        FIGURE 37 PARTICLE THERAPY MARKET: COMPANY EVALUATION MATRIX, 2022
     12.6 COMPETITIVE BENCHMARKING FOR KEY PLAYERS 
             12.6.1 PARTICLE THERAPY MARKET: COMPANY FOOTPRINT
                        TABLE 135 OVERALL COMPANY FOOTPRINT (10 COMPANIES)
                        TABLE 136 TYPE FOOTPRINT (10 COMPANIES)
                        TABLE 137 PRODUCT & SERVICE FOOTPRINT (10 COMPANIES)
                        TABLE 138 SYSTEM FOOTPRINT (10 COMPANIES)
                        TABLE 139 CANCER TYPE FOOTPRINT (10 COMPANIES)
                        TABLE 140 APPLICATION FOOTPRINT (10 COMPANIES)
                        TABLE 141 REGIONAL FOOTPRINT (10 COMPANIES)
     12.7 STARTUP/SME EVALUATION MATRIX 
             12.7.1 PROGRESSIVE COMPANIES
             12.7.2 RESPONSIVE COMPANIES
             12.7.3 DYNAMIC COMPANIES
             12.7.4 STARTING BLOCKS
                        FIGURE 38 PARTICLE THERAPY MARKET: STARTUP/SME EVALUATION MATRIX, 2022
             12.7.5 COMPETITIVE BENCHMARKING FOR STARTUPS/SMES
                        TABLE 142 OVERALL COMPANY FOOTPRINT
                        TABLE 143 TYPE FOOTPRINT
                        TABLE 144 PRODUCT & SERVICE FOOTPRINT
                        TABLE 145 SYSTEM FOOTPRINT
                        TABLE 146 CANCER TYPE FOOTPRINT
                        TABLE 147 APPLICATION FOOTPRINT
                        TABLE 148 REGIONAL FOOTPRINT
     12.8 COMPETITIVE SCENARIOS & TRENDS 
             12.8.1 PRODUCT LAUNCHES & APPROVALS
                        TABLE 149 PARTICLE THERAPY MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020−AUGUST 2023)
             12.8.2 DEALS
                        TABLE 150 PARTICLE THERAPY MARKET: DEALS (JANUARY 2020−AUGUST 2023)
             12.8.3 OTHER DEVELOPMENTS
                        TABLE 151 PARTICLE THERAPY MARKET: OTHER DEVELOPMENTS (JANUARY 2020−AUGUST 2023)
 
13 COMPANY PROFILES (Page No. - 167)
     13.1 KEY PLAYERS 
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
             13.1.1 IBA WORLDWIDE
                        TABLE 152 IBA WORLDWIDE: BUSINESS OVERVIEW
                        FIGURE 39 IBA WORLDWIDE: COMPANY SNAPSHOT (2022)
             13.1.2 VARIAN MEDICAL SYSTEMS, INC.
                        TABLE 153 VARIAN MEDICAL SYSTEMS, INC.: BUSINESS OVERVIEW
                        FIGURE 40 VARIAN MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2022)
             13.1.3 HITACHI, LTD.
                        TABLE 154 HITACHI, LTD.: BUSINESS OVERVIEW
                        FIGURE 41 HITACHI, LTD.: COMPANY SNAPSHOT (2021)
             13.1.4 MEVION MEDICAL SYSTEMS
                        TABLE 155 MEVION MEDICAL SYSTEMS: BUSINESS OVERVIEW
             13.1.5 SUMITOMO HEAVY INDUSTRIES LTD.
                        TABLE 156 SUMITOMO HEAVY INDUSTRIES LTD.: BUSINESS OVERVIEW
                        FIGURE 42 SUMITOMO HEAVY INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)
             13.1.6 PROVISION HEALTHCARE, LLC
                        TABLE 157 PROVISION HEALTHCARE, LLC: BUSINESS OVERVIEW
             13.1.7 TOSHIBA MEDICAL SYSTEMS CORPORATION
                        TABLE 158 TOSHIBA MEDICAL SYSTEMS CORPORATION: BUSINESS OVERVIEW
                        FIGURE 43 TOSHIBA MEDICAL SYSTEMS CORPORATION: COMPANY SNAPSHOT (2022)
             13.1.8 OPTIVUS PROTON THERAPY, INC.
                        TABLE 159 OPTIVUS PROTON THERAPY, INC.: BUSINESS OVERVIEW
             13.1.9 PROTOM INTERNATIONAL, INC.
                        TABLE 160 PROTOM INTERNATIONAL, INC.: BUSINESS OVERVIEW
             13.1.10 ADVANCED ONCOTHERAPY PLC
                        TABLE 161 ADVANCED ONCOTHERAPY PLC: BUSINESS OVERVIEW
     13.2 OTHER PLAYERS 
             13.2.1 DANFYSIK A/S
                        TABLE 162 DANFYSIK A/S: BUSINESS OVERVIEW
             13.2.2 P-CURE, LTD.
                        TABLE 163 P-CURE, LTD.: BUSINESS OVERVIEW
             13.2.3 PTW FREIBURG GMBH
                        TABLE 164 PTW FREIBURG GMBH: BUSINESS OVERVIEW
 
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
 
14 APPENDIX (Page No. - 194)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS 

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the particle therapy market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in product therapy markets. The primary sources from the demand side include medical OEMs, Analytical instrument OEMs, CDMOs, and service providers, among others. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.

A breakdown of the primary respondents is provided below:

Particle  Therapy Market Size, and Share

*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note: Companies are classified into tiers based on their total revenue. As of 2021, Tier 1 = >USD 2 billion, Tier 2 = USD 50 million to USD 2 billion, and Tier 3 = <USD 50 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Estimation Methodology

In this report, the global particle therapy market size was arrived at by using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the particle therapy market business were determined through various insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and key marketing executives.

To calculate the global market value, segmental revenues were calculated based on the revenue mapping of major solution/service providers. This process involved the following steps:

  • Generating a list of major global players operating in the particle therapy market.
  • Mapping annual revenues generated by major global players from the global particle therapy market (or nearest reported business unit/product category)
  • Revenue mapping of key  players to cover a major share of the global market, as of 2022
  • Extrapolating the global value of the particle therapy market

Particle  Therapy Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After arriving at the overall market size from the market size estimation process explained above, the global particle therapy market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the particle therapy market was validated using both top-down and bottom-up approaches.

Market Definition

Particle therapy is an advanced modality of external beam radiotherapy that uses positively charged particles such as protons or heavy ions for cancer treatment. Particle therapy offers a more precise and effective mode of radiation, which accurately targets tumors and minimizes damage to healthy tissues.

Key Stakeholders

  • Radiotherapy product manufacturers
  • Distributors, suppliers, and commercial service providers
  • Healthcare service providers
  • Clinical research organizations (CROs)
  • Radiotherapy service providers
  • Radiotherapy product distributors
  • Medical research laboratories
  • Cancer care centers
  • Cancer research organizations
  • Academic medical centers and universities
  • Market research and consulting firms

Objectives of the Study

  • To define, describe, and forecast the particle therapy market based on product,type, system, application, cancer type and region.
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze the micro markets with respect to individual growth trends, prospects, and contributions to the total market.
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders.
  • To profile the key market players and comprehensively analyze their market shares and core competencies.
  • To forecast the revenue of the market segments with respect to five main regions, namely, North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), the Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa.
  • To track and analyze competitive developments such as new product launches and approvals; agreements, partnerships, expansions, acquisitions; and collaborations in the particle therapy market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present global particle therapy market

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolios of the top thirteen companies.

Company Information

  • Detailed analysis and profiling of additional market players (up to 13)

Geographic Analysis

  • Further breakdown of the Rest of Europe's particle therapy market into Russia, Belgium, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal among other
  • Further breakdown of the Rest of Asia Pacific particle therapy market into Singapore, Taiwan, New Zealand, Philippines, Malaysia, and other APAC countries
  • Further breakdown of the Rest of the world particle therapy market into Latin America, MEA, and Africa
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 6747
Published ON
Nov, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Particle Therapy Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback